Published in Oncogene on March 29, 2010
Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J (2013) 1.26
Predictive Bcl-2 family binding models rooted in experiment or structure. J Mol Biol (2012) 1.09
LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis (2013) 1.06
Characterization of an arachidonic acid-deficient (Fads1 knockout) mouse model. J Lipid Res (2012) 1.03
EphA2 activation promotes the endothelial cell inflammatory response: a potential role in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 1.02
Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene (2012) 1.00
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95
Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol. J Anesth (2011) 0.91
The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis (2012) 0.87
Eicosanoid pathway in colorectal cancer: Recent updates. World J Gastroenterol (2015) 0.81
RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. J Exp Med (2016) 0.81
Nutrient stress alters the glycosylation status of LGR5 resulting in reduced protein stability and membrane localisation in colorectal tumour cells: implications for targeting cancer stem cells. Br J Cancer (2015) 0.77
The hallmarks of cancer. Cell (2000) 113.05
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (1999) 11.96
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 11.09
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell (2001) 9.33
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
ER stress triggers apoptosis by activating BH3-only protein Bim. Cell (2007) 7.50
BAX activation is initiated at a novel interaction site. Nature (2008) 6.07
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol (2000) 6.05
Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell (2008) 5.75
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A (2004) 5.55
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem (2003) 4.55
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci (1994) 4.38
Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol (2003) 4.25
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene (2003) 3.96
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med (2007) 3.58
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell (2005) 3.19
COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol (2005) 3.15
Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol (2007) 3.11
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ (2005) 3.00
Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol (1996) 2.87
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A (1998) 2.83
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol (2000) 2.53
Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene (2005) 2.36
Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem (2003) 2.31
The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer (2007) 2.29
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J (2001) 1.97
Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res (1996) 1.97
ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J (2007) 1.90
Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol (2009) 1.83
Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A (2007) 1.83
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell (2009) 1.77
Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 1.76
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res (2005) 1.68
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res (2006) 1.64
Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res (1990) 1.57
Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res (2006) 1.43
Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene (2007) 1.38
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene (2008) 1.38
BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene (1994) 1.34
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A (2003) 1.30
Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem (2004) 1.26
Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ (2006) 1.19
Specific cytogenetic abnormalities in two new human colorectal adenoma-derived epithelial cell lines. Cancer Res (1989) 1.17
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol (2002) 1.17
Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene (2006) 1.13
Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med (2009) 1.09
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res (2008) 1.08
The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene (2007) 0.98
COX-2 inhibitors for colorectal cancer. Nat Med (1998) 0.97
BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis (2008) 0.96
Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res (2004) 0.86
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis (2000) 0.81
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res (1990) 5.70
KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst (1996) 4.16
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
The APC gene product in normal and tumor cells. Proc Natl Acad Sci U S A (1993) 3.25
Problems in assessing contents of metered dose inhalers. BMJ (1993) 3.07
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res (1997) 2.33
Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene (2008) 2.26
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
The isolation and characterization of colorectal epithelial cell lines at different stages in malignant transformation from familial polyposis coli patients. Int J Cancer (1984) 2.04
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene (1999) 2.00
Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate. Gastroenterology (1997) 1.99
Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer (1993) 1.94
Starch-Ampicillin Agar for the Quantitative Detection of Aeromonas hydrophila. Appl Environ Microbiol (1985) 1.72
Minimum standards for the management of cleft lip and palate: efforts to close the audit loop. Royal College of Surgeons of England. Ann R Coll Surg Engl (1996) 1.72
An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene (1999) 1.64
Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol (1992) 1.62
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res (1990) 1.57
Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer (1995) 1.54
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett (1990) 1.47
Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci (1999) 1.45
Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res (2000) 1.44
Influence of surgeon's experience on speech outcome in cleft lip and palate. Lancet (1999) 1.44
Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci (2008) 1.43
Migraine after bone-marrow transplantation. Lancet (1989) 1.43
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
Colorectal cancer and dietary calcium intervention: a word of caution. Eur J Cancer Prev (1992) 1.39
The incidence of impacted teeth. A survey at Harlem hospital. Oral Surg Oral Med Oral Pathol (1970) 1.35
A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. Oncogene (1988) 1.35
BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene (1994) 1.34
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation. Am J Respir Crit Care Med (2000) 1.33
Submandibular duct sialolith of unusual size and shape. J Oral Surg (1975) 1.31
Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev (2003) 1.30
A study to determine the reasons for differences in the tumorigenicity of rat cell lines transformed by adenovirus 2 and adenovirus 12. Cold Spring Harb Symp Quant Biol (1980) 1.27
The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. Mol Biol Cell (2000) 1.26
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology (1999) 1.25
Sexual difficulties of chronic pain patients. Clin J Pain (2001) 1.25
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene (1997) 1.23
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. Cleft Palate Craniofac J (2001) 1.21
Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech Dev (2000) 1.21
Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ (2006) 1.19
Systematic review of outpatient services for chronic pain control. Health Technol Assess (1997) 1.19
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (1985) 1.17
Xenobiotic metabolism in motor neuron disease. Lancet (1988) 1.16
Xenobiotic metabolism in Parkinson's disease. Neurology (1989) 1.16
Tumorigenicity and in vitro characteristics of rat liver epithelial cells and their adenovirus-transformed derivatives. Int J Cancer (1980) 1.15
Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm (2000) 1.15
Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem (1998) 1.14
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. Cleft Palate Craniofac J (2001) 1.12
Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res (2000) 1.12
Characterisation of adherens and tight junctional molecules in normal animal larynx; determining a suitable model for studying molecular abnormalities in human laryngopharyngeal reflux. J Clin Pathol (2005) 1.10
Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer (1999) 1.10
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol (1990) 1.10
O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur J Biochem (1994) 1.09
The development of a battery of measures for assessing physical functioning of chronic pain patients. Pain (1994) 1.08
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer (2000) 1.08
Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis (1997) 1.07
Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut (2000) 1.06
Spinal cord stimulation and the relief of chronic pain. J Neurol Neurosurg Psychiatry (1987) 1.06
Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines. Int J Cancer (1989) 1.06
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 1: background and methodology. Cleft Palate Craniofac J (2001) 1.03
TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer (1993) 1.02
Extrapyramidal reactions to anti-inflammatory drugs. J Neurol Neurosurg Psychiatry (1988) 1.02
The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Proc Nutr Soc (1996) 1.02
A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int J Cancer (2000) 1.01
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer (1970) 1.01
Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res (1994) 1.01
Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science (1979) 1.01
Smoking habits of Florida physicians revisited. JFMA (1972) 1.01
Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J Pharm Pharmacol (1999) 1.01
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut (2005) 1.00
Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene (2012) 1.00
Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 1.00
Patients' and professionals' understandings of the causes of chronic pain: blame, responsibility and identity protection. Soc Sci Med (1997) 0.99
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther (2003) 0.99
Motoneurone disease as manifestation of pesticide toxicity. Lancet (1987) 0.99
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut (1994) 0.99
Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet (1996) 0.98
Expression of CDX2 in normal and neoplastic human colon tissue and during differentiation of an in vitro model system. Gut (2002) 0.98
Derepression of synthesis of the aminoacyl-transfer ribonucleic acid synthetases for the branched-chain amino acids of Escherichia coli. J Bacteriol (1974) 0.98
Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J Pharm Pharmacol (2001) 0.98
Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology (1990) 0.98
COX-2 inhibitors for colorectal cancer. Nat Med (1998) 0.97
Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer (1994) 0.97
Bax inhibitor 1 in apoptosis and disease. Oncogene (2011) 0.97
bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int J Cancer (1997) 0.96